Hyperfine Data From NEURO PMR Trial Of Portable MRI Demonstrates 92% Concordance With Standard MRI Identifying Presence Or Absence Of Intracranial Pathology

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the NEURO PMR study, presented by Dr. Laszlo Mechtler at the American Society of Neuroimaging (ASN) Annual Meeting in San Juan, Puerto Rico on January 16, 2026.

NEURO PMR (Neurological Evaluation in the Office with Portable MR) is the first prospective, multi-center, real-world study to evaluate the clinical utility and patient experience of portable MRI compared to standard-of-care MRI in outpatient neurology clinics. Two sites—DENT Neurologic Institute and Texas Neurology—enrolled 125 patients with neurologic conditions commonly seen in the outpatient setting, including headache, dementia, multiple sclerosis follow-up, and tumor surveillance. Patients received brain imaging on both the portable Swoop® system (0.064T) and a conventional high-field MRI (primarily 3T), enabling direct modality comparisons.

Portable MRI demonstrated 92% concordance with standard MRI in identifying the presence or absence of intracranial pathology during a blinded review by independent neuroradiologists. In unblinded paired image reviews incorporating clinical history, concordance increased to 98%, as assessed by a neurologist and neuroimager. Patients expressed a strong preference for portable MRI, reporting that they were four times more likely to choose it over standard MRI. Across all experience measures—including comfort, anxiety, claustrophobia, noise, and overall satisfaction—portable MRI was rated superior to standard MRI (p<0.0001). Trained clinical staff successfully operated the system within neurology offices without the need for MR technologists, highlighting its safe and simple workflow.